Clinical Trials Logo
  1. Home
  2. Obsessive-Compulsive Disorder
  3. NCT01108393
  4. Details
NCT01108393 Clinical Trial

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder Clinical Trial

Official title:
Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01108393
Other study ID # CL2-20098-072
Secondary ID 2009-016713-20
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2010
Est. completion date April 2013

Study information
Verified date January 2020
Source Servier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the efficacy of agomelatine compared to placebo on the reduction of Obsessive and Compulsive symptoms after 16 weeks of treatment.

Recruitment information / eligibility
Status Completed
Enrollment 74
Est. completion date April 2013
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Obsessive Compulsive Disorder (OCD) according to Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR),

- Y-BOCS total score = 20,

- duration of OCD symptoms of at least one year.

Exclusion Criteria:

- Bipolar disorder, Schizophrenic or Psychotic Disorder

- Severe or uncontrolled organic diseases

- Neurological disorder

- Women of childbearing potential who are not using effective contraception

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Agomelatine A
Agomelatine 25 mg film-coated tablet Agomelatine 2x25mg film-coated tablet
• Placebo
Placebo

Locations
Country Name City State
Israel Department of Psychiatry Chaim Sheba Medical Center Tel Hashomer

Sponsors (1)
Lead Sponsor Collaborator
Institut de Recherches Internationales Servier

Country where clinical trial is conducted

Israel, 

Outcome
Type Measure Description Time frame Safety issue
Primary Y-BOCS total score Yale-Brown Obsessive Compulsive scale (Y-BOCS) total score. This scale measures the severity of obsessive and compulsive symptoms from baseline to W16. 16 weeks
Secondary NIMH-OC score National Institute for Mental Health- Obsessive Compulsive scale (NIMH-OC) Total Score. This scale measures the severity of obsessive and compulsive symptoms from baseline to week 16. 16 weeks
Secondary MADRS total score Montgomery and Asberg Depression rating scale (MADRS) Total score. This scale measures the severity of depressive symptoms from baseline to week 16. 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed NCT02229903 - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD N/A
Completed NCT02202915 - CBT for Pediatric OCD: Community Training Pilot N/A
Completed NCT01794156 - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder N/A
Completed NCT02089984 - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders N/A
Completed NCT01348529 - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Completed NCT01172873 - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD N/A
Completed NCT00723060 - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Phase 4
Not yet recruiting NCT00743834 - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Phase 4
Completed NCT02421315 - Overlapping Neural Circuits in Pediatric OCD N/A
Completed NCT02194075 - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Phase 4
Completed NCT01981317 - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder N/A
Completed NCT01686087 - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder N/A
Completed NCT01331876 - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy N/A
Terminated NCT00997087 - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder Phase 2
Completed NCT00533806 - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Phase 3
Completed NCT00517244 - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders N/A
Completed NCT00169377 - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) Phase 1/Phase 2

External Links